LUGPA Bladder Cancer Highlights: Key Trials and Trends for 2025

Sia Daneshmand, MD, of Keck Medicine of USC, talks about the biggest developments and key highlights in bladder cancer from the LUGPA 2024 Annual Meeting, including the recent approval of ANKTIVA and the SunRISe-1 study of the TAR-200 drug delivery system for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.

Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 will take place September 27-29 in Nashville, Tennessee.

This meeting is the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Sia Daneshmand, MDUrothelial Carcinoma | November 20, 2024
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
View More
Irbaz B. Riaz, MBBS, PhDSPCS 2024 | November 5, 2024
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
Irbaz B. Riaz, MBBS, PhDSPCS 2024 | November 5, 2024
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
Irbaz B. Riaz, MBBS, PhDSPCS 2024 | November 5, 2024
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.

Video Insights

Clinical discussions with experts in the field

Network Websites